Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Leore T. Geller; Michal Barzily-Rokni; Tal Danino; Oliver Jonas; Noam Shental; Deborah Nejman; Nancy Gavert; Yaara Zwang; Zachary A. Cooper; Kevin Shee; Christoph A. Thaiss; Alexandre Reuben; Jonathan Livny; Roi Avraham; Dennie T. Frederick; Matteo Ligorio; Kelly Chatman; Stephen Johnston; Carrie M. Mosher; Alexander Brandis; Garold Fuks; Candice R. Gurbatri; Vancheswaran Gopalakrishnan; Michael P. Kim; Mark W. Hurd; Matthew H. G. Katz; Jason B. Fleming; Anirban Maitra; David A. Smith; Matt Skalak; Jeffrey Bu; Monia Michaud; Sunia A. Trauger; Iris Barshack; Talia Golan; Judith Sandbank; Keith T. Flaherty; Anna Mandinova; Wendy S. Garrett; Sarah P. Thayer; Cristina R. Ferrone; Curtis Huttenhower; Sangeeta N. Bhatia; Dirk Gevers; Jennifer A. Wargo; Todd R. Golub; Ravid Straussman

doi:10.1126/science.aah5043

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Leore T. Geller(Weizmann Institute of Science), Michal Barzily-Rokni(Broad Institute), Tal Danino(Massachusetts Institute of Technology), Oliver Jonas(Brigham and Women's Hospital), Noam Shental(Open University of Israel), Deborah Nejman(Weizmann Institute of Science), Nancy Gavert(Weizmann Institute of Science), Yaara Zwang(Weizmann Institute of Science), Zachary A. Cooper(The University of Texas MD Anderson Cancer Center), Kevin Shee(Broad Institute), Christoph A. Thaiss(Weizmann Institute of Science), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Jonathan Livny(Broad Institute), Roi Avraham(Weizmann Institute of Science), Dennie T. Frederick(Massachusetts General Hospital), Matteo Ligorio(Massachusetts General Hospital), Kelly Chatman(Harvard University Press), Stephen Johnston(Broad Institute), Carrie M. Mosher(Broad Institute), Alexander Brandis(Weizmann Institute of Science), Garold Fuks(Weizmann Institute of Science), Candice R. Gurbatri(Columbia University), Vancheswaran Gopalakrishnan(The University of Texas MD Anderson Cancer Center), Michael P. Kim(The University of Texas MD Anderson Cancer Center), Mark W. Hurd(The University of Texas MD Anderson Cancer Center), Matthew H. G. Katz(The University of Texas MD Anderson Cancer Center), Jason B. Fleming(The University of Texas MD Anderson Cancer Center), Anirban Maitra(The University of Texas MD Anderson Cancer Center), David A. Smith(Broad Institute), Matt Skalak(Massachusetts Institute of Technology), Jeffrey Bu(Massachusetts Institute of Technology), Monia Michaud(Harvard University), Sunia A. Trauger(Harvard University Press), Iris Barshack(Tel Aviv University), Talia Golan(Tel Aviv University), Judith Sandbank(Tel Aviv University), Keith T. Flaherty(Massachusetts General Hospital), Anna Mandinova(Broad Institute), Wendy S. Garrett(Broad Institute), Sarah P. Thayer(University of Nebraska Medical Center), Cristina R. Ferrone(Massachusetts General Hospital), Curtis Huttenhower(Broad Institute), Sangeeta N. Bhatia(Broad Institute), Dirk Gevers(Broad Institute), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Todd R. Golub(Broad Institute), Ravid Straussman(Weizmann Institute of Science)

Science

September 14, 2017

10.1126/science.aah5043

Cited by 1,743Open Access

Full Text

Abstract

expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that of the 113 human PDACs that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria.

Related Papers

No related papers found

Powered by citation graph analysis